These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 28696418)

  • 1. Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis.
    Loft ND; Skov L; Iversen L; Gniadecki R; Dam TN; Brandslund I; Hoffmann HJ; Andersen MR; Dessau RB; Bergmann AC; Andersen NM; Andersen PS; Bank S; Vogel U; Andersen V
    Pharmacogenomics J; 2018 May; 18(3):494-500. PubMed ID: 28696418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologic drug survival in Israeli psoriasis patients.
    Shalom G; Cohen AD; Ziv M; Eran CB; Feldhamer I; Freud T; Berman E; Oren S; Hodak E; Pavlovsky L
    J Am Acad Dermatol; 2017 Apr; 76(4):662-669.e1. PubMed ID: 28038888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations between functional polymorphisms in the NFκB signaling pathway and response to anti-TNF treatment in Danish patients with inflammatory bowel disease.
    Bank S; Andersen PS; Burisch J; Pedersen N; Roug S; Galsgaard J; Turino SY; Brodersen JB; Rashid S; Rasmussen BK; Avlund S; Olesen TB; Hoffmann HJ; Thomsen MK; Thomsen VØ; Frydenberg M; Nexø BA; Sode J; Vogel U; Andersen V
    Pharmacogenomics J; 2014 Dec; 14(6):526-34. PubMed ID: 24776844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry.
    Zweegers J; van den Reek JM; van de Kerkhof PC; Otero ME; Kuijpers AL; Koetsier MI; Arnold WP; Berends MA; Weppner-Parren L; Ossenkoppele PM; Njoo MD; Mommers JM; van Lümig PP; Driessen RJ; Kievit W; de Jong EM
    Br J Dermatol; 2016 Aug; 175(2):340-7. PubMed ID: 26989852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of Fcγ receptor polymorphisms in the response to anti–tumor necrosis factor therapy in psoriasis A pharmacogenetic study.
    Julià M; Guilabert A; Lozano F; Suarez-Casasús B; Moreno N; Carrascosa JM; Ferrándiz C; Pedrosa E; Alsina-Gibert M; Mascaró JM
    JAMA Dermatol; 2013 Sep; 149(9):1033-9. PubMed ID: 24048425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]).
    Strober BE; Bissonnette R; Fiorentino D; Kimball AB; Naldi L; Shear NH; Goyal K; Fakharzadeh S; Calabro S; Langholff W; You Y; Galindo C; Lee S; Lebwohl MG
    J Am Acad Dermatol; 2016 May; 74(5):851-61.e4. PubMed ID: 26853180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologic Therapies in HIV-infected Patients with Psoriasis: An Italian Experience.
    Bardazzi F; Magnano M; Campanati A; Loconsole F; Carpentieri A; Potenza C; Bernardini N; Di Lernia V; Carrera C; Raone B; Patrizi A; Loi C
    Acta Derm Venereol; 2017 Aug; 97(8):989-990. PubMed ID: 28512671
    [No Abstract]   [Full Text] [Related]  

  • 8. Etanercept, adalimumab, and ustekinumab in psoriasis: analysis of 209 treatment series in Austria.
    Richter L; Vujic I; Sesti A; Monshi B; Sanlorenzo M; Posch C; Rappersberger K
    J Dtsch Dermatol Ges; 2017 Mar; 15(3):309-317. PubMed ID: 28240404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose Modification in Biologic Therapy for Moderate to Severe Psoriasis: A Descriptive Analysis in a Clinical Practice Setting.
    Baniandrés O; Rodríguez-Soria VJ; Romero-Jiménez RM; Suárez R
    Actas Dermosifiliogr; 2015 Sep; 106(7):569-77. PubMed ID: 25935194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world efficacy of biological agents in moderate-to-severe plaque psoriasis: An analysis of 75 patients in Taiwan.
    Chen YC; Huang YT; Yang CC; Lai EC; Liu CH; Hsu CK; Wong TW; Chao SC; Sheu HM; Lee CN
    PLoS One; 2020; 15(12):e0244620. PubMed ID: 33373425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on TNF Inhibitors.
    Kerdel FA
    Semin Cutan Med Surg; 2016 Jun; 35(4 Suppl 4):S67-70. PubMed ID: 27526035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Pharmacogenetic Study of Psoriasis Risk Variants in a Greek Population and Prediction of Responses to Anti-TNF-α and Anti-IL-12/23 Agents.
    Masouri S; Stefanaki I; Ntritsos G; Kypreou KP; Drakaki E; Evangelou E; Nicolaidou E; Stratigos AJ; Antoniou C
    Mol Diagn Ther; 2016 Jun; 20(3):221-5. PubMed ID: 27043841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis.
    Prieto-Pérez R; Llamas-Velasco M; Cabaleiro T; Solano-López G; Márquez B; Román M; Ochoa D; Talegón M; Daudén E; Abad-Santos F
    Pharmacogenomics; 2017 Jan; 18(2):157-164. PubMed ID: 27977334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphisms in CD84, IL12B and TNFAIP3 are associated with response to biologics in patients with psoriasis.
    van den Reek JMPA; Coenen MJH; van de L'Isle Arias M; Zweegers J; Rodijk-Olthuis D; Schalkwijk J; Vermeulen SH; Joosten I; van de Kerkhof PCM; Seyger MMB; Zeeuwen PLJM; de Jong EMGJ
    Br J Dermatol; 2017 May; 176(5):1288-1296. PubMed ID: 27564082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Functional Polymorphisms on Drug Survival of Biological Therapies in Patients with Moderate-to-Severe Psoriasis.
    Membrive-Jiménez C; Pérez-Ramírez C; Arias-Santiago S; Richetta AG; Ottini L; Pineda-Lancheros LE; Ramírez-Tortosa MDC; Jiménez-Morales A
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The polymorphism rs763780 in the IL-17F gene is associated with response to biological drugs in patients with psoriasis.
    Prieto-Pérez R; Solano-López G; Cabaleiro T; Román M; Ochoa D; Talegón M; Baniandrés O; López Estebaranz JL; de la Cueva P; Daudén E; Abad-Santos F
    Pharmacogenomics; 2015; 16(15):1723-31. PubMed ID: 26415694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of biological therapies in patients with psoriasis with alcoholic cirrhosis: a French retrospective study of 23 cases.
    Begon E; Beneton N; Poiraud C; Droitcourt C; Jacobzone C; Vermersch-Langlin A; Descamps V; Perrot JL; Khemis A; Pallure V; Fougerousse AC; Sigal-Grinberg M; Schmutz JL; Goujon C; Reguiai Z;
    Br J Dermatol; 2018 Aug; 179(2):512-513. PubMed ID: 29480522
    [No Abstract]   [Full Text] [Related]  

  • 18. Routine Laboratory Parameter Dynamics and Laboratory Adverse Events in Psoriasis Patients on Long-term Treatment with Adalimumab, Etanercept, and Ustekinumab.
    Hoffmann JH; Knoop C; Enk AH; Hadaschik EN
    Acta Derm Venereol; 2017 Jun; 97(6):705-710. PubMed ID: 28224166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the 1- and 5-year effectiveness of adalimumab, etanercept and ustekinumab in patients with psoriasis in daily clinical practice: results from the prospective BioCAPTURE registry.
    Zweegers J; Groenewoud JMM; van den Reek JMPA; Otero ME; van de Kerkhof PCM; Driessen RJB; van Lümig PPM; Njoo MD; Ossenkoppele PM; Mommers JM; Koetsier MIA; Arnold WP; Andriessen MPM; Kuijpers ALA; Berends MAM; Kievit W; de Jong EMGJ
    Br J Dermatol; 2017 Apr; 176(4):1001-1009. PubMed ID: 27579864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weight gain and tumour necrosis factor-alpha inhibitors in patients with psoriasis.
    Tan E; Baker C; Foley P
    Australas J Dermatol; 2013 Nov; 54(4):259-63. PubMed ID: 24164178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.